株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

RNA干渉 (RNAi) の世界市場

RNA Interference (RNAi)

発行 Global Industry Analysts, Inc. 商品コード 240220
出版日 ページ情報 英文 792 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=114.58円で換算しております。

ご注意:Single user licenseはDRM(デジタル著作権管理システム)付PDFとなります。
PDFの閲覧には Adobe Digital Editions (無償)のインストールが必要となります。
認証されたPC上のみでの閲覧と、1回のプリントアウトが可能となっております。

Back to Top
RNA干渉 (RNAi) の世界市場 RNA Interference (RNAi)
出版日: 2012年04月01日 ページ情報: 英文 792 Pages
概要

当レポートでは、RNA干渉 (RNAi) の世界市場を応用分野別に分析し、米国/カナダ/日本/欧州/アジア太平洋/その他の地域についての包括的な地域別分析を提供し、2009-2017年間の年間業績を推定/予測するとともに6年間の歴史的分析、及び主要/ニッチプレーヤ135社の企業プロファイルを盛り込み、概略下記の構成でお届けいたします。

第1章 イントロダクション、方法論、製品定義

第2章 エグゼクティブサマリ

第3章 業界展望

  • RNA干渉:歴史的展望
  • RNAi年表

第4章 業界概要

  • 主要地域市場
  • ハイスループット・スクリーニング:RNA干渉の有望なアプリケーション
  • 成長牽引力

第5章 市場展望

  • RNA干渉:可能性のあるオリゴヌクレオチド技術
  • siRNAと競合するオリゴヌクレオチドの主要クラスのレビュー
  • オリゴヌクレオチド市場の継続する不況
  • パイプライン中の主要RNAiベース治療薬
  • RNAi:遺伝子抑制における主要研究ツール
  • 新たな治療薬クラスとして出現するRNAiベースの薬剤
  • RNAi市場の成長をけん引するRNAiベースの薬剤
  • 主要疾病の統計
  • 心臓血管系疾患
  • ハンチントン病
  • 糖尿病性網膜症
  • 薬剤治療におけるRNAi
  • RNAi:主要標的臨床分野
  • 加齢性黄斑変性症:焦点となる主要臨床分野
  • パイプライン中の有望な主要RNAi薬剤:レビュー
  • RNAi治療薬:課題の概要
  • ドラッグデリバリー:RNAiベースの治療薬に直面する主な課題
  • その他の課題
  • 開発中のRNAiデリバリー・プラットフォームの概要

第6章 製品概要

  • RNA干渉の歴史
  • コサプレッションとクエリング
  • VIGS (ウィルス誘発性遺伝子抑制)
  • RNA干渉または転写後サイレンシング
  • RNAi経路
  • siRNAとmiRNA
  • RISC複合体
  • 転移と継承
  • 相違
  • RNA干渉を仲介するその他の短いRNA
  • RNA干渉における多様なタイプのRNAの比較

第7章 RNA干渉のアプリケーション

  • RNA干渉の重要性
  • 遺伝子サイレンシングにおけるRNAiの役割
  • 翻訳レベルでの蛋白質合成に影響するRNA干渉
  • 遺伝子出現におけるmRNAの役割
  • RNAi:応用分野
  • 創薬とターゲット検証におけるRNAi
  • RNAi試薬
  • siRNA合成
  • RNAiのその他の応用分野のレビュー
  • 農業と植物バイオテクノロジーにおけるRNAi

第8章 規制的承認

第9章 技術的革新

第10章 最近の業界活動

第11章 戦略的企業発展:歴史的展望材料

第12章 世界の主要プレーヤへの焦点

第13章 世界市場展望

  • 米国
  • カナダ
  • 日本
  • 欧州
    • フランス
    • ドイツ
    • イタリア
    • 英国
    • その他
  • アジア太平洋
  • その他の地域

第14章 競合状況

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: MCP-6819

This report analyzes the worldwide markets for RNA Interference (RNAi) in US$ Million by the following application areas: Drug Discovery and Target Validation, Reagents, and siRNA Synthesis. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2017. Also, a six-year historic analysis is provided for these markets. The report profiles 135 companies including many key and niche players such as Alnylam Pharmaceuticals, Inc., Benitec Limited, Bioneer Corp., Calando Pharmaceuticals, Inc., Cenix BioScience GmbH, Devgen NV, Dharmacon, Inc., Dicerna Pharmaceuticals, Inc., Exiqon A/S, Genesis Research & Development Corporation Limited, Halo-Bio RNAi Therapeutics, Inc., Marina Biotech, Inc., OPKO Health, Inc., Polyplus-transfection SA, Quark Pharmaceuticals, Inc., Galena Biopharma, Sigma-Aldrich Co., Silence Therapeutics, and Tekmira Pharmaceuticals Corp. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain.

Table of Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

  • Study Reliability and Reporting Limitations
    • Disclaimers
  • Data Interpretation & Reporting Level
    • Quantitative Techniques & Analytics
  • Product Definitions and Scope of Study
    • Product Segments
      • Drug Discovery and Target Validation
      • Reagents
      • SiRNA Synthesis

II. EXECUTIVE SUMMARY

1. INDUSTRY OUTLOOK

  • RNA Interference: A Historic Perspective
  • RNAi Time Line

2. INDUSTRY OVERVIEW

  • Leading Regional Markets
  • High-throughput Screening: A Promising Application for RNA Interference
  • Growth Drivers

3. MARKET OUTLOOK

  • RNA Interference: A Potential Oligonucleotide Technology
  • A Review of Select Classes of Oligonucleotides Competing with siRNA
  • Oligonucleotide Market Sustains Recession
  • Select RNAi-based Therapeutics in the Pipeline
  • RNAi: A Leading Research Tool in Gene-Silencing
  • RNAi-based Drugs to Emerge as a New Class of Therapeutics
  • RNAi-based Therapeutics to Drive the Growth of RNAi Market
  • Statistics on Select Diseases
  • Cancer
    • Table 1: Global Cancer Incidence by Region: 2009 (includes corresponding Graph/Chart)
    • Table 2: Global Cancer Incidence by Country: 2009 (includes corresponding Graph/Chart)
    • Table 3: Global Cancer Incidence by Income Group: 2009 (includes corresponding Graph/Chart)
    • Table 4: Global Cancer Related Deaths in Male Population by Site: 2007 (includes corresponding Graph/Chart)
    • Table 5: Global Cancer Related Deaths in Female Population by Site: 2007(includes corresponding Graph/Chart)
  • Cardiovascular Diseases
    • Table 6: Global Coronary Heart Disease Prevalence by Region (includes corresponding Graph/Chart)
    • Table 7: Deaths Due to Major Cardiovascular Diseases in the US: Percentage Share Breakdown by Disease Type (includes corresponding Graph/Chart)
  • Huntington's Disease (HD)
  • Diabetic Retinopathy
    • Table 8: Diabetic Retinopathy Patient Prevalence in the US by Diabetes Type: 2006-2015 (In Thousand Patients) (includes corresponding Graph/Chart)
    • Table 9: Diabetic Retinopathy Patient Prevalence in the US by Age Group: 2006-2012 (includes corresponding Graph/Chart)
    • Table 10: Diabetic Retinopathy Prevalence in Type-1 Diabetic Patients in the US by Age Group: 2006-2012 (includes corresponding Graph/Chart)
  • RNAi in Drug Therapeutics
  • RNAi: Select Targeted Clinical Areas
  • Age Related Macular Degeneration: A Key Clinical Area of Focus
  • Select Promising RNAi Drugs in Pipeline: A Review
  • ALN-VSP
  • Atu027
  • CALAA-01
  • CEQ501
  • RNAi Therapeutics: Challenges in a Nutshell
  • Drug Delivery: A Key Challenge Facing RNAi-based Therapeutics
  • Select Methods of Systemic Drug Delivery under Development
  • Select RNAi Drug Delivery Technologies under Development
  • Other Challenges Facing RNAi-based Therapeutics
  • A Snapshot of Select RNAi Delivery Platforms Under Development
  • Lipid Nanoparticle (LNP) siRNA Delivery Technology Platform (Tekmira)
  • RONDEL (Calando Pharmaceuticals)
  • Lipid and Polymer Based Delivery Platforms (Silence Therapeutics)
    • AtuPlex/AtuFect Delivery Platform
    • PolyTran™ Delivery Platform
  • RNAi Nanoplex Delivery Technology (Intradigm Corporation)
  • DiLA2 Platform (Marina Biotech)

4. PRODUCT OVERVIEW

  • History of RNA Interference
  • Co-Suppression and Quelling
  • VIGS (Virus Induced Gene Suppression)
  • RNA Interference or Post Transcriptional Silencing
  • The RNAi Pathway
  • siRNA and miRNA
  • RISC Complex
  • Transfer and Heritance
  • The Difference
  • Other Short RNAs mediating RNA Interference
  • Small Hairpin RNA (shRNA)
  • Repeat associated small interfering RNA (rasiRNA)
  • Comparison of Various Types of RNAs in RNA Interference

5. APPLICATIONS OF RNA INTERFERENCE

  • Significance of RNA Interference
  • Role of RNAi in Gene Silencing
  • RNA Interference Affects Protein Synthesis at the Level of Translation
  • Role of mRNA in Gene Expression
  • RNAi: Application Areas
  • RNAi in Drug Discovery and Target Validation
    • RNAi in Functional Genomics
      • Why RNAi over Other Techniques?
      • Use of RNAi in the Study of Functional Genomics in Humans
      • Model Organisms and Off-target Effects
    • Select Target Validation Systems
      • RNAiMonitor™ (Clontech Laboratories, Inc)
      • GenoExplorer™ microRNA System (GenoSensor Corp)
  • RNAi Reagents
    • Select RNAi Reagents and Transfection Kits
      • Lipofectamine™ RNAiMAX Transfection Reagent (Life Technologies/Invitrogen)
      • siGENOME® siRNA Reagents (Dharmacon RNA Technologies)
      • ON-TARGETplus™ SMARTpool Reagents (Dharmacon RNA Technologies)
      • Vector-based RNAi Reagents (Thermo Scientific)
      • siRNA transfection kits (Bio-Rad Lab)
      • Fluorescent Reagents (OZ Biosciences)
      • ICAFectin™ 442 siRNA Transfection Reagent (Tekmira)
      • TransIT®-mRNA Transfection Kit (Mirus Bio llc)
  • siRNA Synthesis
    • siRNA: A Popular Tool for the Detection and Induction of Gene Silencing
    • Methods of siRNA Synthesis
    • Select Synthetic siRNAs
      • Synthetic siRNAs (Eurogentec SA)
      • Ambion® In Vivo Pre-designed siRNAs (Life Technologies)
      • Silencer® Pre-Designed & Validated siRNAs (Life Technologies)
      • HuSH-29: pre-designed shRNA (OriGene Technologies, Inc.)
  • A Review of other Application Areas of RNAi
  • RNAi in Agriculture and Plant Biotechnology
    • miRNA as Biomarkers and Therapeutic Targets - An Insight
    • miRNA: Clinical Areas under Focus

6. REGULATORY APPROVALS

  • Asuragen Obtains Notices of Allowance for Several miRNA Patent Applications
  • Genable Technologies Obtains Orphan Designation by EMA
  • Benitec Obtains RNA Interference Patent from EPO
  • Silence Therapeutics Bags New Patent Rights
  • Benitec Receives RNAi Related Patent Grant from USPTO
  • Marina Obtains Notices of Allowance for siRNA Patent Applications
  • USPTO Grants a RNAi Related Patent to Benitec
  • Alnylam Receives Patent Rights for Woppmann Patent Series
  • Kylin Bags Patent Rights for pRNAi Technology
  • Allele Biotechnology Obtains Patent Approval for DNA-Encoded RNAi
  • Silence Therapeutics Obtains Notices of Allowance for RNAi Patent Applications
  • RXi Obtains Notices of Allowance for siRNA Patent Applications
  • Intradigm Obtains Patent for siRNA Sequence
  • Intradigm Receives Key RNAi Patent Allowance

7. TECHNOLOGICAL INNOVATIONS

  • Exiqon Launches miRCURY LNA™ miRNA Family Inhibitors
  • Cellecta Introduces New Open Source Genome-Wide RNAi Screening Platform
  • Tekmira, Alnylam, and UBC Co-Develop New Lipid Component
  • ID Tech Introduces Improved miRCat™ Small RNA Cloning System
  • Integrated DNA Technologies Launches Transductin™
  • Abnova Unveils New Gene Silencing Tool
  • Polyplus-transfection Introduces jetPRIME™ Transfection Reagent
  • Sigma-Aldrich Launches Gene-Specific MISSION esiRNA
  • CombiMatrix to Introduce miRNA Cancer-Screening Test in the US
  • GeneCopoeia Unveils microRNA Tools and Reagents for Functional Analysis
  • Invitrogen Introduces Invivofectamine™ Delivery Reagent

8. RECENT INDUSTRY ACTIVITY

  • RXi Pharmaceuticals Corp. is Now Galena Biopharma
  • Cenix to Establish New Subsidiary
  • Arrowhead Acquires Stake in US Subsidiary, Calando
  • RXi and Generex Obtain Positive Research Data for Exploring RNAi Technology
  • Rosetta Obtains Permit for miRNA-based Diagnostics in NY
  • Alnylam Pharmaceuticals Introduces Alnylam 5x15 Product Strategy
  • Cenix BioScience Receives R&D Grant from Saxony
  • Kyowa and Dicerna Expand Research Collaboration
  • MDRNA Acquires BNA Intellectual Property from Valeant
  • Sirnaomics Partners with a Chinese Company for RNAi Therapeutics Development
  • Kylin Obtains IRS Grant for Advancing Research on pRNAi Nanoparticle
  • Tekmira Obtains New License for Alnylam's InterfeRx™
  • RXi to Collaborate with EyeGate
  • Sigma Life Partners with SwitchGear Genomics for miRNA Validation System
  • Marina Biotech Acquires Novosom's SMARTICLES® Intellectual Property Estate
  • Quark to Collaborate with Nitto Denko for Co-Developing siRNA-based Anti-fibrotic Drug
  • AstraZeneca and Silence Therapeutics Extend R&D Alliance
  • Silence Therapeutics and AstraZeneca Extend siRNA Delivery Partnership
  • MDRNA to Take Over Cequent
  • Traversa and sanofi-aventis Ink Research Agreement
  • Pfizer to Develop HCV Compounds of Tacere Therapeutics
  • Intradigm and Silence Therapeutics Merge
  • Sirna Therapeutics and Allergan form Joint Drug Development Alliance
  • Benitec Collaborates with CCIA
  • RXi Pharmaceuticals Obtains Advirna's RNAi Technology
  • RXi Obtains Exclusive Licensing Rights to Advirna's Delivery Technologies
  • Dicerna Collaborates with Archemix
  • Alnylam Collaborates with GSK to Donate Several RNAi Technology Patents
  • AstraZeneca and Cenix Extend Research Agreement on RNA Interference
  • Allergan Stops Development of AGN-745 Treatment
  • Tekmira Inks Agreement with Roche
  • MDRNA Inks Licensing Agreement with Novartis
  • MDRNA Inks Agreement with Roche for Developing RNAi Therapeutics
  • Mirna Therapeutics to Investigate Therapeutic Potential of miRNA
  • Cenix and Boehringer Ingelheim Ink Research Agreement
  • Mirna and M. D. Anderson to Explore miRNA Therapeutics in Prostate Cancer
  • Cubist Partners with Alnylam Pharmaceuticals
  • Liquidia to License Certain Rights of PRINT technology to Abbott

9. STRATEGIC CORPORATE DEVELOPMENTS - A HISTORIC PERSPECTIVE BUILDER

  • Invitrogen Merges with Applied Biosystems
  • MDRNA Obtains Rights to RiboTask's UNA Technology
  • Roche Takes Over Mirus
  • Thermo Fischer Snaps Up Open Biosystems
  • Protiva and Tekmira Complete the Merger of Business Operations
  • Takeda and Alnylam Enter into Strategic Alliance
  • SR Pharma Plc. is Now Silence Therapeutics Plc.

10. FOCUS ON SELECT GLOBAL PLAYERS

  • Alnylam Pharmaceuticals, Inc. (USA)
  • Benitec Limited (Australia)
  • Bioneer Corp. (Korea)
  • Calando Pharmaceuticals, Inc. (USA)
  • Cenix BioScience GmbH (Germany)
  • Devgen NV (Belgium)
  • Dharmacon, Inc. (USA)
  • Dicerna Pharmaceuticals, Inc. (USA)
  • Exiqon A/S (Denmark)
  • Genesis Research & Development Corporation Limited (New Zealand)
  • Halo-Bio RNAi Therapeutics, Inc. (USA)
  • Marina Biotech, Inc. (USA)
  • OPKO Health, Inc. (USA)
  • Polyplus-transfection SA (France)
  • Quark Pharmaceuticals, Inc. (USA)
  • Galena Biopharma (USA)
  • Sigma-Aldrich Co. (USA)
  • Silence Therapeutics (UK)
  • Tekmira Pharmaceuticals Corp. (Canada)

11. GLOBAL MARKET PERSPECTIVE

    • Table 11: World Recent Past, Current & Future Analysis for RNA Interference by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 12: World Historic Review for RNA Interference by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
    • Table 13: World 15-Year Perspective for RNA Interference by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific, and Rest of World for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)
    • Table 14: World Recent Past, Current & Future Analysis for RNA Interference in Drug Discovery and Target Validation Applications by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 15: World Historic Review for RNA Interference in Drug Discovery and Target Validation Applications by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
    • Table 16: World 15-Year Perspective for RNA Interference in Drug Discovery and Target Validation Applications by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific, and Rest of World for Years 2003, 2011 & 2017(includes corresponding Graph/Chart)
    • Table 17: World Recent Past, Current & Future Analysis for RNA Interference Reagents by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 18: World Historic Review for RNA Interference Reagents by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
    • Table 19: World 15-Year Perspective for RNA Interference Reagents by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific, and Rest of World for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)
    • Table 20: World Recent Past, Current & Future Analysis for siRNA Synthesis by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017(includes corresponding Graph/Chart)
    • Table 21: World Historic Review for siRNA Synthesis by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, and Rest of World Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
    • Table 22: World 15-Year Perspective for siRNA Synthesis by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific, and Rest of World for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)

III. MARKET

1. THE UNITED STATES

  • A. Market Analysis
    • Outlook
    • Technological Innovations
    • Strategic Corporate Developments
    • Focus on Select Major Players
  • B. Market Analytics
    • Table 23: The US Recent Past, Current & Future Analysis for RNA Interference Market by Application Area - Drug Discovery and Target Validation, Reagents, and siRNA Synthesis Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 24: The US Historic Review for RNA Interference Market by Application Area - Drug Discovery and Target Validation, Reagents, and siRNA Synthesis Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
    • Table 25: The US 15-Year Perspective for RNA Interference Market by Application Area - Percentage Breakdown of Dollar Sales for Drug Discovery and Target Validation, Reagents, and siRNA Synthesis for Years 2003, 2011 & 2017(includes corresponding Graph/Chart)

2. CANADA

  • A. Market Analysis
    • Strategic Corporate Development
    • Focus on Select Major Player
  • B. Market Analytics
    • Table 26: Canadian Recent Past, Current & Future Analysis for RNA Interference Market by Application Area - Drug Discovery and Target Validation, Reagents, and siRNA Synthesis Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 27: Canadian Historic Review for RNA Interference Market by Application Area - Drug Discovery and Target Validation, Reagents, and siRNA Synthesis Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
    • Table 28: Canadian 15-Year Perspective for RNA Interference Market by Application Area - Percentage Breakdown of Dollar Sales for Drug Discovery and Target Validation, Reagents, and siRNA Synthesis for Years 2003, 2011 & 2017(includes corresponding Graph/Chart)

3. JAPAN

  • A. Market Analysis
    • Strategic Corporate Developments
  • B. Market Analytics
    • Table 29: Japanese Recent Past, Current & Future Analysis for RNA Interference Market by Application Area - Drug Discovery and Target Validation, Reagents, and siRNA Synthesis Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 30: Japanese Historic Review for RNA Interference Market by Application Area - Drug Discovery and Target Validation, Reagents, and siRNA Synthesis Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
    • Table 31: Japanese 15-Year Perspective for RNA Interference Market by Application Area - Percentage Breakdown of Dollar Sales for Drug Discovery and Target Validation, Reagents, and siRNA Synthesis for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)

4. EUROPE

  • Market Analytics
    • Table 32: European Recent Past, Current & Future Analysis for RNA Interference Market by Geographic Region - France, Germany, Italy, UK, and Rest of European Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 33: European Historic Review for RNA Interference by Geographic Region - France, Germany, Italy, UK, and Rest of European Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
    • Table 34: European 15-Year Perspective for RNA Interference by Geographic Region - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, and Rest of European for Years 2003, 2011 & 2017(includes corresponding Graph/Chart)
    • Table 35: European Recent Past, Current & Future Analysis for RNA Interference Market by Application Area - Drug Discovery and Target Validation, Reagents, and siRNA Synthesis Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 36: European Historic Review for RNA Interference Market by Application Area - Drug Discovery and Target Validation, Reagents, and siRNA Synthesis Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
    • Table 37: European 15-Year Perspective for RNA Interference Market by Application Area - Percentage Breakdown of Dollar Sales for Drug Discovery and Target Validation, Reagents, and siRNA Synthesis for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)

4a. FRANCE

  • A. Market Analysis
    • Technological Innovation
    • Strategic Corporate Development
    • Focus on Select Major Player
  • B. Market Analytics
    • Table 38: French Recent Past, Current & Future Analysis for RNA Interference Market by Application Area - Drug Discovery and Target Validation, Reagents, and siRNA Synthesis Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 39: French Historic Review for RNA Interference Market by Application Area - Drug Discovery and Target Validation, Reagents, and siRNA Synthesis Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
    • Table 40: French 15-Year Perspective for RNA Interference Market by Application Area - Percentage Breakdown of Dollar Sales for Drug Discovery and Target Validation, Reagents, and siRNA Synthesis for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)

4b. GERMANY

  • A. Market Analysis
    • Strategic Corporate Developments
  • B. Market Analytics
    • Table 41: German Recent Past, Current & Future Analysis for RNA Interference Market by Application Area - Drug Discovery and Target Validation, Reagents, and siRNA Synthesis Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017(includes corresponding Graph/Chart)
    • Table 42: German Historic Review for RNA Interference Market by Application Area - Drug Discovery and Target Validation, Reagents, and siRNA Synthesis Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
    • Table 43: German 15-Year Perspective for RNA Interference Market by Application Area - Percentage Breakdown of Dollar Sales for Drug Discovery and Target Validation, Reagents, and siRNA Synthesis for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)

4c. ITALY

  • Market Analytics
    • Table 44: Italian Recent Past, Current & Future Analysis for RNA Interference Market by Application Area - Drug Discovery and Target Validation, Reagents, and siRNA Synthesis Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 45: Italian Historic Review for RNA Interference Market by Application Area - Drug Discovery and Target Validation, Reagents, and siRNA Synthesis Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
    • Table 46: Italian 15-Year Perspective for RNA Interference Market by Application Area - Percentage Breakdown of Dollar Sales for Drug Discovery and Target Validation, Reagents, and siRNA Synthesis for Years 2003, 2011 & 2017(includes corresponding Graph/Chart)

4d. THE UNITED KINGDOM

  • A. Market Analysis
    • Technological Innovations
    • Focus on Select Major Player
  • B. Market Analytics
    • Table 47: The UK Recent Past, Current & Future Analysis for RNA Interference Market by Application Area - Drug Discovery and Target Validation, Reagents, and siRNA Synthesis Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 48: The UK Historic Review for RNA Interference Market by Application Area - Drug Discovery and Target Validation, Reagents, and siRNA Synthesis Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
    • Table 49: The UK 15-Year Perspective for RNA Interference Market by Application Area - Percentage Breakdown of Dollar Sales for Drug Discovery and Target Validation, Reagents, and siRNA Synthesis for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)

4e. REST OF EUROPE

  • A. Market Analysis
    • Strategic Corporate Developments
    • Focus on Select Major Players
  • B. Market Analytics
    • Table 50: Rest of European Recent Past, Current & Future Analysis for RNA Interference Market by Application Area - Drug Discovery and Target Validation, Reagents, and siRNA Synthesis Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 51: Rest of European Historic Review for RNA Interference Market by Application Area - Drug Discovery and Target Validation, Reagents, and siRNA Synthesis Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
    • Table 52: Rest of European 15-Year Perspective for RNA Interference Market by Application Area - Percentage Breakdown of Dollar Sales for Drug Discovery and Target Validation, Reagents, and siRNA Synthesis for Years 2003, 2011 & 2017(includes corresponding Graph/Chart)

5. ASIA-PACIFIC

  • A. Market Analysis
    • Strategic Corporate Developments
    • Focus on Select Major Players
  • B. Market Analytics
    • Table 53: Asia-Pacific Recent Past, Current & Future Analysis for RNA Interference Market by Application Area - Drug Discovery and Target Validation, Reagents, and siRNA Synthesis Independently nalyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 54: Asia-Pacific Historic Review for RNA Interference Market by Application Area - Drug Discovery and Target Validation, Reagents, and siRNA Synthesis Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
    • Table 55: Asia-Pacific 15-Year Perspective for RNA Interference Market by Application Area - Percentage Breakdown of Dollar Sales for Drug Discovery and Target Validation, Reagents, and siRNA Synthesis for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)

6. REST OF WORLD

  • Market Analytics
    • Table 56: Rest of World Recent Past, Current & Future Analysis for RNA Interference Market by Application Area - Drug Discovery and Target Validation, Reagents, and siRNA Synthesis Independently Analyzed with Annual Sales Figures in US$ Million for Years 2009 through 2017 (includes corresponding Graph/Chart)
    • Table 57: Rest of World Historic Review for RNA Interference Market by Application Area - Drug Discovery and Target Validation, Reagents, and siRNA Synthesis Independently Analyzed with Annual Sales Figures in US$ Million for Years 2003 through 2008 (includes corresponding Graph/Chart)
    • Table 58: Rest of World 15-Year Perspective for RNA Interference Market by Application Area - Percentage Breakdown of Dollar Sales for Drug Discovery and Target Validation, Reagents, and siRNA Synthesis for Years 2003, 2011 & 2017 (includes corresponding Graph/Chart)

IV. COMPETITIVE LANDSCAPE

Back to Top